References
- Henderson S, Andrews G, Hall W. Australia's mental health: an overview of the general population survey. Australian and New Zealand Journal of Psychiatry 2000; 34: 197–205
- Hirschfeld RM, Schatzberg AF. Long-term management of depression. American Journal of Medicine 1994; 97: 33S–38S
- Bertolote JM, Fleischmann A, De Leo D, Wasserman D. Psychiatric diagnoses and suicide: revisiting the evidence. Crisis 2004; 25: 147–155
- Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. Journal of Clinical Psychiatry 2002; 63: 685–693
- Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 2004; 55: 296–300
- Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatrica Scandinavica 2001; 103: 66–72
- Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. Journal of Clinical Psychopharmacology 1999; 19: 177–182
- Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 2006; 354: 1243–1252
- Dodd, S, Horgan, D, Malhi, GS, Berk, M. To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders. 2005; 89: 1–11
- Fava, M, Rush, AJ, Trivedi, MH, , et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatric Clinics of North America 2003; 26: 457–494.
- Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press, Cambridge 2000